Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.
Pharmacy Department, Faculty of Science and Technology, Mandala Waluya University, Kendari 93561, Indonesia.
Molecules. 2022 Jun 7;27(12):3661. doi: 10.3390/molecules27123661.
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, having a poor prognosis and rapid metastases. TNBC is characterized by the absence of estrogen, progesterone, and human epidermal growth receptor-2 (HER2) expressions and has a five-year survival rate. Compared to other breast cancer subtypes, TNBC patients only respond to conventional chemotherapies, and even then, with limited success. Shortages of chemotherapeutic medication can lead to resistance, pressured index therapy, non-selectivity, and severe adverse effects. Finding targeted treatments for TNBC is difficult owing to the various features of cancer. Hence, identifying the most effective molecular targets in TNBC pathogenesis is essential for predicting response to targeted therapies and preventing TNBC cell metastases. Nowadays, natural compounds have gained attention as TNBC treatments, and have offered new strategies for solving drug resistance. Here, we report a systematic review using the database from Pubmed, Science Direct, MDPI, BioScince, Springer, and Nature for articles screening from 2003 to 2022. This review analyzes relevant signaling pathways and the prospect of utilizing natural compounds as a therapeutic agent to improve TNBC treatments in the future.
三阴性乳腺癌（TNBC）是乳腺癌中侵袭性最强的亚型，预后不良且转移迅速。TNBC 的特征是缺乏雌激素、孕激素和人表皮生长因子受体 2（HER2）的表达，五年生存率低。与其他乳腺癌亚型相比，TNBC 患者仅对常规化疗有反应，即使有反应，成功率也有限。化疗药物的短缺会导致耐药性、压力指数治疗、非选择性和严重的不良反应。由于癌症的各种特征，寻找针对 TNBC 的靶向治疗方法很困难。因此，确定 TNBC 发病机制中最有效的分子靶标对于预测靶向治疗的反应和防止 TNBC 细胞转移至关重要。如今，天然化合物已成为 TNBC 治疗的关注点，并为解决药物耐药性提供了新的策略。在这里，我们使用 Pubmed、Science Direct、MDPI、BioScince、Springer 和 Nature 数据库，对 2003 年至 2022 年的文章进行了系统回顾。该综述分析了相关信号通路，并探讨了利用天然化合物作为治疗剂改善 TNBC 治疗的前景。
